Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research
Stocks in this Quantisnow insightHealth Care
Historical context for ILMN
Across the 27 sessions after earlier ILMN headlines, the stock closed higher 14 times and lower 13 times, with a median move of 1.2% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | ILMN | SPY |
|---|---|---|---|
| May 22, 2026 | David P. King elected to Illumina's Board of Directors | -0.3% | +0.4% |
| May 20, 2026 | Illumina releases 2025 Corporate Responsibility Report, expanding access to genomics and accelerating global impact | +0.2% | +1.0% |
| May 15, 2026 | RBC Capital Mkts resumed coverage on Illumina with a new price target | -0.5% | -1.2% |
| May 14, 2026 | Illumina upgraded by Daiwa Securities with a new price target | -1.2% | +0.8% |
| May 1, 2026 | Illumina Reports Financial Results for First Quarter of Fiscal Year 2026 | +7.1% | +0.3% |
| Apr 16, 2026 | DRAGEN v4.5 supports Illumina's new TruPath Genome and 5-base assays, drives insights across germline, oncology, and multiomic workflows | +0.3% | +0.2% |
Quantisnow market dataNASDAQ
ILMN
Illumina Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Medical Specialities
- Listed since
- 2000
Get push alerts for ILMN
Full ILMN profile on Quantisnow Follow ILMN and get a push notification the moment its next story breaks.